Prescient Therapeutics Limited (USD) Operating from Melbourne, Australia, Prescient Therapeutics Limited is a clinical-stage oncology company dedicated to pioneering novel pharmaceutical treatments for a variety of cancers. The company's primary investigational therapy, PTX-200, is currently undergoing several advanced clinical trials: a Phase 2a study for HER2-negative breast cancer, a Phase 1B/2 trial addressing relapsed and refractory acute myeloid leukemia (AML), and a Phase 1b trial for platinum-resistant ovarian cancer that has recurred or persisted. Another key pipeline asset is PTX-100, a RhoA inhibitor, engineered to combat both blood and solid tumors, particularly those characterized by specific Ras and RhoA genetic mutations. Furthermore, Prescient maintains a strategic partnership with The University of Texas MD Anderson Cancer Center, focused on the development of a novel blood cancer binder for their OmniCAR platform. Established in 1986, the company adopted its current name, Prescient Therapeutics Limited, in December 2014, having previously operated as Virax Holdings Limited.

Prescient Therapeutics Limited (USD) Passive

100 Albert Road, Melbourne, VIC, AU, 3205

Stock Price USD

Price Change

Last Dividend USD

PSTTF's stock peer is AAPGV (Ascentage Pharma Group International)

PSTTF's stock peer is ADOIF (Adocia S.A.)

PSTTF's stock peer is AMEUF (Anteris Technologies Ltd)

PSTTF's stock peer is AMGXF (AnGes, Inc.)

PSTTF's stock peer is CMXC (Cell MedX Corp.)

PSTTF's stock peer is COLRF (China Medical & HealthCare Group Limited)

PSTTF's stock peer is EPRXF (Eupraxia Pharmaceuticals Inc.)

PSTTF's stock peer is JMDMF (Japan Medical Dynamic Marketing, Inc.)

PSTTF's stock peer is LFLY (Leafly Holdings, Inc.)

PSTTF's stock peer is MCURF (Mind Cure Health Inc.)

Healthcare Biotechnology

Operating from Melbourne, Australia, Prescient Therapeutics Limited is a clinical-stage oncology company dedicated to pioneering novel pharmaceutical treatments for a variety of cancers. The company's primary investigational therapy, PTX-200, is currently undergoing several advanced clinical trials: a Phase 2a study for HER2-negative breast cancer, a Phase 1B/2 trial addressing relapsed and refractory acute myeloid leukemia (AML), and a Phase 1b trial for platinum-resistant ovarian cancer that has recurred or persisted. Another key pipeline asset is PTX-100, a RhoA inhibitor, engineered to combat both blood and solid tumors, particularly those characterized by specific Ras and RhoA genetic mutations. Furthermore, Prescient maintains a strategic partnership with The University of Texas MD Anderson Cancer Center, focused on the development of a novel blood cancer binder for their OmniCAR platform. Established in 1986, the company adopted its current name, Prescient Therapeutics Limited, in December 2014, having previously operated as Virax Holdings Limited.

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Yield	Dividend Frequency
2026-06-15	2026-06-25	0.00 %	Semi-Annual
2025-11-27	2025-12-16	0.00 %	Semi-Annual
2025-06-18	2025-07-01	0.92 %	Semi-Annual
2024-11-25	2024-12-12	0.81 %	Semi-Annual
2024-06-13	2024-06-28	0.70 %	Semi-Annual
2023-11-24	2023-12-14	0.77 %	Semi-Annual
2023-06-09	2023-06-16	0.85 %	Semi-Annual
2022-12-01	2022-12-12	0.73 %	Semi-Annual
2022-06-07	2022-06-22	0.47 %	Semi-Annual
2021-12-03	2021-12-15	1.14 %	Semi-Annual
2021-06-08	2021-06-16	0.91 %	Semi-Annual
2019-06-11	2019-06-21	0.86 %	Semi-Annual

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions